Therapeutic compositions comprising imidazole and imidazolium compounds
View Patent ↗Therapeutic compositions comprising substituted imidazole or imidazolium compounds may be used for a number of medical purposes, such as treatment of undesirable conditions or diseases, including disease or conditions related to bone, cancer, and/or pain.
1. A method of treating musculoskeletal pain comprising administering a pharmaceutical composition to a mammal in need thereof, wherein the pharmaceutical composition comprises:
in an amount that is less than 0.1% w/w, and greater than 0%; or
in an amount that is less than 0.1% w/w, and greater than 0% w/w;
wherein any amount in % w/w is based upon the total weight of Compound A, Compound B, and Compound C;
wherein each A is independently an acidic functional group.
2. The method of claim 1 , wherein the musculoskeletal pain comprises back pain, pain in extremity, joint pain, or muscle pain.
3. A method of treating musculoskeletal pain comprising administering a pharmaceutical composition to a mammal in need thereof, wherein the pharmaceutical composition comprises:
zoledronic acid; and
in an amount that is less than 0.1% w/w, and greater than 0% w/w; or
in an amount that is less than 0.1% w/w, and greater than 0% w/w;
wherein any amount in % w/w is based upon the total weight of zoledronic acid, Compound 1, and Compound 2.
4. The method of claim 3 , wherein the pharmaceutical composition is administered orally in an amount and frequency that results in an AUC of zoledronic acid, over a four week period, that is about 100 ng·h/mL to about 2000 ng·h/mL.
5. The method of claim 3 , wherein the pharmaceutical composition is administered orally in an amount that results in an AUC of zoledronic acid, over a twenty-four hour period, that is about 20 ng·h/mL to about 500 ng·h/mL.
6. The method of claim 3 , wherein the musculoskeletal pain comprises back pain.
7. The method of claim 6 , wherein the pharmaceutical composition is administered in an amount such that a monthly dose of zoledronic acid is about 1 mg to about 600 mg.
8. The method of claim 7 , wherein the pharmaceutical composition is administered orally.
9. The method of claim 3 , wherein the musculoskeletal pain comprises pain in an extremity.
10. The method of claim 9 , wherein the pharmaceutical composition is administered in an amount such that a monthly dose of zoledronic acid is about 1 mg to about 600 mg.
11. The method of claim 10 , wherein the pharmaceutical composition is administered orally.
12. The method of claim 3 , wherein the musculoskeletal pain comprises joint pain.
13. The method of claim 12 , wherein the pharmaceutical composition is administered in an amount such that a monthly dose of zoledronic acid is about 1 mg to about 600 mg.
14. The method of claim 13 , wherein the pharmaceutical composition is administered orally.
15. The method of claim 3 , wherein the musculoskeletal pain comprises muscle pain.
16. The method of claim 15 , wherein the pharmaceutical composition is administered in an amount such that a monthly dose of zoledronic acid is about 1 mg to about 600 mg.
17. The method of claim 16 , wherein the pharmaceutical composition is administered orally.
18. A method of treating complex regional pain syndrome comprising administering a pharmaceutical composition to a mammal in need thereof, wherein the pharmaceutical composition comprises:
zoledronic acid; and
in an amount that is less than 0.1% w/w, and greater than 0% w/w; or
in an amount that is less than 0.1% w/w, and greater than 0% w/w;
wherein any amount in % w/w is based upon the total weight of zoledronic acid, Compound 1, and Compound 2.
19. The method of claim 18 , wherein the pharmaceutical composition is administered in an amount such that a monthly dose of zoledronic acid is about 1 mg to about 600 mg.
20. The method of claim 19 , wherein the pharmaceutical composition is administered orally.
21. The method of claim 18 , wherein the pharmaceutical composition is administered orally in an amount and frequency that results in an AUC of zoledronic acid, over a four week period, that is about 100 ng·h/mL to about 2000 ng·h/mL.
22. The method of claim 18 , wherein the pharmaceutical composition is administered orally in an amount that results in an AUC of zoledronic acid, over a twenty-four hour period, that is about 20 ng·h/mL to about 500 ng·h/mL.
23. A method of treating ankylosing spondylitis comprising administering a pharmaceutical composition to a mammal in need thereof, wherein the pharmaceutical composition comprises:
zoledronic acid; and
in an amount that is less than 0.1% w/w, and greater than 0% w/w; or
in an amount that is less than 0.1% w/w, and greater than 0% w/w;
wherein any amount in % w/w is based upon the total weight of zoledronic acid, Compound 1, and Compound 2.
24. The method of claim 23 , wherein the pharmaceutical composition is administered in an amount such that a monthly dose of zoledronic acid is about 1 mg to about 600 mg.
25. The method of claim 24 , wherein the pharmaceutical composition is administered orally.
26. The method of claim 23 , wherein the pharmaceutical composition is administered orally in an amount and frequency that results in an AUC of zoledronic acid, over a four week period, that is about 100 ng·h/mL to about 2000 ng·h/mL.
27. The method of claim 23 , wherein the pharmaceutical composition is administered orally in an amount that results in an AUC of zoledronic acid, over a twenty-four hour period, that is about 20 ng·h/mL to about 500 ng·h/mL.